Abstract:RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk. Mendelian randomisation (MR) was used to determine whether genetic variations influencing ANGPTL3 liver gene expression, blood levels, and protein structure could causally influence triglyceride and apolipoprotein B (apoB) levels as well as coronary artery disease (CAD), ischaemic stroke (IS), and other cardiometabolic diseases. RNA sequencing of 246 explanted liver samples and genome-wide genotyping was performed to identify single-nucleotide polymorphisms (SNPs) associated with liver expression of ANGPTL3 . Genome-wide summary statistics of plasma protein levels of ANGPTL3 from the deCODE study ( n = 35 359) were used. A total of 647 carriers of ANGPTL3 protein-truncating variants (PTVs) associated with lower plasma triglyceride levels were identified in the UK Biobank. Two-sample MR using SNPs that influence ANGPTL3 liver expression or ANGPTL3 plasma protein levels as exposure and cardiometabolic diseases as outcomes was performed (CAD, IS, heart failure, non-alcoholic fatty liver disease, acute pancreatitis, and type 2 diabetes). The impact of rare PTVs influencing plasma triglyceride levels on apoB levels and CAD was also investigated in the UK Biobank. In two-sample MR studies, common genetic variants influencing ANGPTL3 hepatic or blood expression levels of ANGPTL3 had a very strong effect on plasma triglyceride levels, a more modest effect on low-density lipoprotein cholesterol, a weaker effect on apoB levels, and no effect on CAD or other cardiometabolic diseases. In the UK Biobank, the carriers of rare ANGPTL3 PTVs providing lifelong reductions in median plasma triglyceride levels [−0.37 (interquartile range 0.41) mmol/L] had slightly lower apoB levels (−0.06 ± 0.32 g/L) and similar CAD event rates compared with non-carriers (10.2% vs. 10.9% in carriers vs. non-carriers, P = .60). PTVs influencing ANGPTL3 protein structure as well as common genetic variants influencing ANGPTL3 hepatic expression and/or blood protein levels exhibit a strong effect on circulating plasma triglyceride levels, a weak effect on circulating apoB levels, and no effect on ASCVD. Near-complete inhibition of ANGPTL3 function in patients with very elevated apoB levels may be required to reduce ASCVD risk. ANGPTL3, angiopoietin-like protein-3; LDL, low-density lipoprotein; RNA, ribonucleic acid; SNP, single-nucleotide polymorphism.

Abstract 16650: EDEM3 Modulates the Plasma Triglyceride Level via Its Regulation of LRP1 Expression

EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression

506-P: Regulation of ANGPTL3 by SEL1L-HRD1 ER-Associated Degradation

Abstract 115: Angptl3 Deficiency Impairs Triglyceride-rich Lipoprotein Production and Produces Adaptive Changes in Hepatic Lipid Metabolism

Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3

ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk

New Insights into ANGPLT3 in Controlling Lipoprotein Metabolism and Risk of Cardiovascular Diseases

Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel PPARG frameshift mutation c.418dup

Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

The emerging role of ethanolamine phosphate phospholyase in regulating hepatic phosphatidylethanolamine and plasma lipoprotein metabolism in mice

Abstract 113: Endothelial Argonaute 1: A Novel Regulator Of Hyperlipidemia And Atherosclerosis

Role of Drosophila EDEMs in the degradation of the alpha-1-antitrypsin Z variant

Abstract 242: Functional Characterization of a Cis-eQTL Locus for Plasma Cholesterol Using CRISPR/Cas Genome Editing in Human Pluripotent Stem Cells

ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization

LET-767 Determines Lipid Droplet Protein Targeting and Lipid Homeostasis.

Erratum: A Rare Variant in APOC3 is Associated with Plasma Triglyceride and VLDL Levels in Europeans

Abstract 117: A Genome-wide CRISPR/Cas9 Knockout Screen Reveals New Targets To Increase Cellular LDL Uptake.

ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors

DNA Hypermethylation: A Novel Mechanism of CREG Gene Suppression and Atherosclerogenic Endothelial Dysfunction.